hotspot -WSS

hotspot

author：comprehensive 2025-10-02 23:48:01 - browse：182

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Bird flu surveillance in wastewater gets boost from consortium

WSS

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Addressing health care workers' trauma can help fight burnout

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Doctors push to include dialysis machines in emergency stockpile

Wikipedia

hotspot

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Novavax promises a turnaround & Lilly roils the obesity market

NFL doctors' conflicts of interest could endanger players, report says

Alkermes shareholders re

How CRISPR works, explained in two minutes

Continuity nursing helped my family in our darkest PICU moments

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Walensky prepares to leave CDC — and Congress — behind

Many breast cancer patients receive more radiation than needed

explore

Biogen joins immunology wave with $1.15 billion acquisition of HI

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Doctors are clamoring for more clarity on Paxlovid prescribing

FDA poised to publish guidelines for clinical trial diversity

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Paxlovid rebound happens. Why and to whom are still a mystery

focus

hotspot

leisure time

hotspot